Advanced Cell Technology to Present at BIO-Europe Spring 2013

  Advanced Cell Technology to Present at BIO-Europe Spring 2013

        ACT to Participate on Panel About Stem Cells in Drug Discovery

BIO-Europe Spring 2013

Business Wire

MARLBOROUGH, Mass. -- March 8, 2013

Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of
regenerative medicine, announced today that chairman and CEO Gary Rabin will
present and participate on a panel at BIO-Europe Spring 2013, March 11-13, in
Barcelona, Spain.

Mr. Rabin’s PowerPoint presentation will be available on the Presentations
section of the ACT website.

Following are specific details regarding Mr. Rabin’s presentation and panel
participation on-site at the conference at Centre Convencions Internacional
Barcelona (CCIB):

Panel:          
Session Title:     Stem cells in drug discovery: New opportunities for
                   biotech-pharma collaboration
Date:              Monday, March 11, 2013
Time:              4 p.m. CET
Room:              Level 1, Room 123
                   
Presentation:
Date:              Tuesday, March 12
Time:              4 p.m. CET
Room:              Level 1, Room 119
                   

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc., is a biotechnology company applying cellular
technology in the field of regenerative medicine. For more information, visit
www.advancedcell.com.

Forward-Looking Statements

Statements in this news release regarding future financial and operating
results, future growth in research and development programs, potential
applications of our technology, opportunities for the company and any other
statements about the future expectations, beliefs, goals, plans, or prospects
expressed by management constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Any
statements that are not statements of historical fact (including statements
containing the words “will,” “believes,” “plans,” “anticipates,” “expects,”
“estimates,” and similar expressions) should also be considered to be
forward-looking statements. There are a number of important factors that could
cause actual results or events to differ materially from those indicated by
such forward-looking statements, including: limited operating history, need
for future capital, risks inherent in the development and commercialization of
potential products, protection of our intellectual property, and economic
conditions generally. Additional information on potential factors that could
affect our results and other risks and uncertainties are detailed from time to
time in the company’s periodic reports, including the report on Form 10-K for
the year ended December 31, 2011. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. Forward-looking statements are based on the
beliefs, opinions, and expectations of the company’s management at the time
they are made, and the company does not assume any obligation to update its
forward-looking statements if those beliefs, opinions, expectations, or other
circumstances should change. There can be no assurance that the Company’s
clinical trials will be successful.

Contact:

Investors:
CEOcast, Inc.
James Young, 212-732-4300
or
Press:
ACT Corporate Communications
Bill Douglass, 646-450-3615
or
Russo Partners
Martina Schwarzkopf, Ph.D., 212-845-4292
 
Press spacebar to pause and continue. Press esc to stop.